Adjuvant Nivolumab & Low Dose Ipilimumab for Stage III & Resected Stage IV Melanoma

Effective adjuvant treatment can increase cure in patients with high-risk resected melanoma. High dose interferon is a standard of care in the adjuvant setting but is highly toxic and marginally effective. The combination of ipilimumab and nivolumab is the most active regimen in patients with advanced melanoma so there is clear rationale to test this regimen in the adjuvant setting. Investigators are testing if nivolumab 3mg/kg every 2 weeks with 1mg/kg ipilimumab every 6 weeks in the high risk adjuvant setting. The duration of therapy will be six months.

NCT Number	NCT02656706
Lead Sponsor	Brown University Collaborators: Rhode Island Hospital, The Miriam Hospital
Conditions	Melanoma
Enrollment	22 participants
Start Date	2016-07
Primary Completion	2019-03 (estimated)
Study Completion	2026-06 (estimated)
Updated on ClinicalTrials.gov	2026-04-13